Literature DB >> 26380626

Adherence to Ibrutinib Therapy Improves Outcomes in Patients with CLL.

Laura Morgan.   

Abstract

Entities:  

Year:  2015        PMID： 26380626      PMCID： PMC4570081     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  3 in total

1.  Impact of dosing frequency (once daily or twice daily) on patient adherence to oral targeted therapies for hematologic malignancies: a retrospective cohort study among managed care enrollees.

Authors:  Krish Patel; Vinjamuri S Sudhir; Shaum Kabadi; Joanna C Huang; Sanchita Porwal; Kushan Thakkar; John M Pagel
Journal:  J Oncol Pharm Pract       Date:  2019-02-05       Impact factor: 1.809

2.  A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment.

Authors:  Aradhana Awasthi; Delphine C M Rolland; Janet Ayello; Carmella van de Ven; Venkatesha Basrur; Kevin Conlon; Damian Fermin; Matthew J Barth; Christian Klein; Kojo S J Elenitoba-Johnson; Megan S Lim; Mitchell S Cairo
Journal:  Oncotarget       Date:  2017-12-09

3.  Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data.

Authors:  Rebecca C Arend; David M O'Malley; Susana Banerjee; Kimmie McLaurin; Richard Davidson; Gráinne H Long
Journal:  Adv Ther       Date:  2021-11-02       Impact factor: 3.845
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.